Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at B.Riley/FBR
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $237.95 +0.71%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
B.Riley/FBR analyst David Buck lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $219.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Assumes Jazz Pharmaceuticals (JAZZ) at Buy
- HCL Technologies (HCLT:IN) PT Lowered to INR1,395 at UBS
- Okta, Inc (OKTA) PT Raised to $230 at BMO Capital on 'AI and Virtuous Cycle Opportunity'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
David BuckSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
